Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto of $16.43 million on lobbying. The Monsanto Company Citizenship Fund aka Monsanto Citizenship Fund is a political action committee that donated over $10 million to various candidates from 2003 to 2013. As of October 2013, Monsanto and DuPont Co. continued backing an anti-labeling campaign, spending roughly $18 million. The state of Washington, along with 26 other states, made proposals in November to require GMO labeling. In the US regulatory environment, many individuals move back and forth between positions in the public and private sectors, including at Monsanto. Critics argued that the connections between the company and the government allowed Monsanto